Literature DB >> 24009088

Use of a faecal immunochemical test narrows current gaps in uptake for sex, age and deprivation in a bowel cancer screening programme.

Jayne Digby1, Paula J McDonald, Judith A Strachan, Gillian Libby, Robert J C Steele, Callum G Fraser.   

Abstract

OBJECTIVES: To investigate the characteristics of participants screened for bowel cancer using a faecal immunochemical test for haemoglobin (FIT).
SETTING: Scottish Bowel Screening Programme.
METHODS: 65909 men and women in two NHS Boards, aged 50 to 74, were invited to participate in an evaluation of FIT as a first-line test. Uptake was calculated by sex, age in quintiles, and deprivation in quintiles, and compared with a group who had completed a guaiac faecal occult blood test (gFOBT) and for whom details of sex, age and deprivation were well documented.
RESULTS: FIT kits from 38672 participants were tested. The overall uptake of 58.7% was significantly higher than the 53.9% for gFOBT (p < 0.0001). Uptakes in the two NHS Boards were 57.6% and 54.4% for men and 63.2% and 59.1% for women, higher than the 49.5% and 58.1% completing gFOBT. Uptake was higher for FIT than gFOBT in all age and deprivation quintiles for both men and women in both NHS Boards. The difference in uptake fell with age for men but rose for women; the increase in uptake was greater for men than women. Uptake fell as deprivation decreased for both sexes, and was similar in both NHS Boards.
CONCLUSIONS: Use of FIT increases uptake over gFOBT, and the greatest increases are seen in men, younger participants, and more deprived individuals, groups for which an increase in uptake is likely to be beneficial. The results support a move to FIT as a first-line screening test for those countries still using gFOBT.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24009088     DOI: 10.1177/0969141313497197

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  10 in total

1.  Improving uptake of screening for colorectal cancer: a study on invitation strategies and different test kit use.

Authors:  Daiga Santare; Ilona Kojalo; Teppo Huttunen; Sergejs Rikacovs; Peteris Rucevskis; Viesturs Boka; Marcis Leja
Journal:  Eur J Gastroenterol Hepatol       Date:  2015-05       Impact factor: 2.566

2.  Reasons for non-participation in the Northern Ireland Bowel Cancer Screening Programme: a qualitative study.

Authors:  Declan T Bradley; Charlene Treanor; Colin McMullan; Tracy Owen; Adele Graham; Diane Anderson
Journal:  BMJ Open       Date:  2015-09-09       Impact factor: 2.692

Review 3.  Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT).

Authors:  James E Allison; Callum G Fraser; Stephen P Halloran; Graeme P Young
Journal:  Gut Liver       Date:  2014-03-11       Impact factor: 4.519

4.  Effects of evidence-based strategies to reduce the socioeconomic gradient of uptake in the English NHS Bowel Cancer Screening Programme (ASCEND): four cluster-randomised controlled trials.

Authors:  Jane Wardle; Christian von Wagner; Ines Kralj-Hans; Stephen P Halloran; Samuel G Smith; Lesley M McGregor; Gemma Vart; Rosemary Howe; Julia Snowball; Graham Handley; Richard F Logan; Sandra Rainbow; Steve Smith; Mary C Thomas; Nicholas Counsell; Steve Morris; Stephen W Duffy; Allan Hackshaw; Sue Moss; Wendy Atkin; Rosalind Raine
Journal:  Lancet       Date:  2015-12-09       Impact factor: 79.321

5.  Long-Term Prediction of the Demand of Colonoscopies Generated by a Population-Based Colorectal Cancer Screening Program.

Authors:  Mercè Comas; Joan Mendivil; Montserrat Andreu; Cristina Hernández; Xavier Castells
Journal:  PLoS One       Date:  2016-10-12       Impact factor: 3.240

6.  A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK.

Authors:  Alan White; Lucy Ironmonger; Robert J C Steele; Nick Ormiston-Smith; Carina Crawford; Amanda Seims
Journal:  BMC Cancer       Date:  2018-09-20       Impact factor: 4.430

7.  What can We Learn From High-Performing Screening Programs to Increase Bowel Cancer Screening Participation in Australia?

Authors:  Louisa Flander; Evelien Dekker; Berit Andersen; Mette Bach Larsen; Robert J Steele; Nea Malila; Tytti Sarkeala; Manon van der Vlugt; Clasine de Klerk; Bart Knottnerus; Lucinda Bertels; Anke Woudstra; Manon C W Spaander; Mirjam Fransen; Sirpa Heinavaara; Mary Dillon; Driss Ait Ouakrim; Mark Jenkins
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

8.  Participant uptake of the fecal immunochemical test decreases with the two-sample regimen compared with one-sample FIT.

Authors:  David M Mosen; Elizabeth G Liles; Adrianne C Feldstein; Nancy Perrin; Anna G Rosales; Erin Keast; David H Smith
Journal:  Eur J Cancer Prev       Date:  2014-11       Impact factor: 2.497

Review 9.  Advances in Fecal Occult Blood Tests: the FIT revolution.

Authors:  Graeme P Young; Erin L Symonds; James E Allison; Stephen R Cole; Callum G Fraser; Stephen P Halloran; Ernst J Kuipers; Helen E Seaman
Journal:  Dig Dis Sci       Date:  2014-12-10       Impact factor: 3.199

10.  Sociodemographic characteristics of nonparticipants in the Danish colorectal cancer screening program: a nationwide cross-sectional study.

Authors:  Mette Bach Larsen; Ellen M Mikkelsen; Morten Rasmussen; Lennart Friis-Hansen; Anders U Ovesen; Hans Bjarke Rahr; Berit Andersen
Journal:  Clin Epidemiol       Date:  2017-06-27       Impact factor: 4.790

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.